(Q38002007)

26 August 2017

Mammalian target of rapamycin and the kidney. II. Pathophysiology and therapeutic implications (English)

1 reference

26 August 2017

1 reference

1 reference

Wilfred Lieberthal

1

1 reference

PubMed ID

22496407

26 August 2017

Jerrold S Levine

series ordinal

2

1 reference

26 August 2017

11 April 2012

1 reference

American Journal of Physiology - Renal Physiology

26 August 2017

1 reference

26 August 2017

303

1 reference

26 August 2017

2

1 reference

26 August 2017

F180-91

1 reference

Clinical and molecular characterization defines a broadened spectrum of autosomal recessive polycystic kidney disease (ARPKD).

26 August 2017

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

New insights into mTOR signaling: mTORC2 and beyond

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Recognition, pathogenesis, and treatment of different stages of nephropathy in patients with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

mTORC1/2 and rapamycin in female Han:SPRD rats with polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Polycystin-1 induces cell migration by regulating phosphatidylinositol 3-kinase-dependent cytoskeletal rearrangements and GSK3beta-dependent cell cell mechanical adhesion

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Polycystin-1 induces resistance to apoptosis through the phosphatidylinositol 3-kinase/Akt signaling pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Primary cilia regulate mTORC1 activity and cell size through Lkb1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Emerging evidence of a link between the polycystins and the mTOR pathways

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Role of polycystins in renal tubulogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Polycystin-1, the gene product of PKD1, induces resistance to apoptosis and spontaneous tubulogenesis in MDCK cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Role of apoptosis in the pathogenesis of acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Rapamycin ameliorates proteinuria-associated tubulointerstitial inflammation and fibrosis in experimental membranous nephropathy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Dedifferentiation and proliferation of surviving epithelial cells in acute renal failure

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Deletion of the TSC2 and PKD1 genes associated with severe infantile polycystic kidney disease--a contiguous gene syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Mouse models of diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Activity of TSC2 is inhibited by AKT-mediated phosphorylation and membrane partitioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Polycystic kidney disease: primary extracellular matrix abnormality or defective cellular differentiation?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Therapeutic mTOR inhibition in autosomal dominant polycystic kidney disease: What is the appropriate serum level?

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Effect of reversible ATP depletion on tight-junction integrity in LLC-PK1 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Approaches to testing new treatments in autosomal dominant polycystic kidney disease: insights from the CRISP and HALT-PKD studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Role of mammalian target of rapamycin signaling in compensatory renal hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

S6 kinase 1 knockout inhibits uninephrectomy- or diabetes-induced renal hypertrophy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Acute kidney injury, mortality, length of stay, and costs in hospitalized patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Regulation of adipocyte differentiation and insulin action with rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

AZD8055 is a potent, selective, and orally bioavailable ATP-competitive mammalian target of rapamycin kinase inhibitor with in vitro and in vivo antitumor activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Introduction: new insights, treatments, and management strategies for ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Metabolic syndrome: a comprehensive perspective based on interactions between obesity, diabetes, and inflammation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Carboxy terminal tail of polycystin-1 regulates localization of TSC2 to repress mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Polycystin-1 regulates extracellular signal-regulated kinase-dependent phosphorylation of tuberin to control cell size through mTOR and its downstream effectors S6K and 4EBP1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Chronic kidney disease progression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Active-site inhibitors of mTOR target rapamycin-resistant outputs of mTORC1 and mTORC2

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Activation of renal signaling pathways in db/db mice with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Activation of the AKT/mTOR pathway in autosomal recessive polycystic kidney disease (ARPKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

21 January 2018

The targeted podocyte

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacerbates the metabolic state in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Sirolimus delays recovery of rat kidney transplants after ischemia-reperfusion injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Ku-0063794 is a specific inhibitor of the mammalian target of rapamycin (mTOR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Cystic diseases of the kidney: ciliary dysfunction and cystogenic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Late progression of renal pathology and cyst enlargement is reduced by rapamycin in a mouse model of nephronophthisis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Role of mTOR in podocyte function and diabetic nephropathy in humans and mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Polycystin-2, the protein mutated in autosomal dominant polycystic kidney disease (ADPKD), is a Ca2+-permeable nonselective cation channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Sirolimus (rapamycin)-based therapy in human renal transplantation: similar efficacy and different toxicity compared with cyclosporine. Sirolimus European Renal Transplant Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Autosomal Recessive Polycystic Kidney Disease: The Clinical Experience in North America

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

The pharmacology of mTOR inhibition

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

mTOR complex 2 is required for the development of prostate cancer induced by Pten loss in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Co-assembly of polycystin-1 and -2 produces unique cation-permeable currents

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Toward a unified theory of renal progression

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Role of mTOR in the degradation of IRS-1: regulation of PP2A activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

A rapamycin-sensitive pathway down-regulates insulin signaling via phosphorylation and proteasomal degradation of insulin receptor substrate-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Comparison of phenotypes of polycystic kidney disease types 1 and 2. European PKD1-PKD2 Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Apoptosis and acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Diabetic kidney lesions of GIPRdn transgenic mice: podocyte hypertrophy and thickening of the GBM precede glomerular hypertrophy and glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Hyperfiltration and glomerulosclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Hypertrophy and hyperfunction of the diabetic kidney

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Chronic rapamycin treatment causes glucose intolerance and hyperlipidemia by upregulating hepatic gluconeogenesis and impairing lipid deposition in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

The polycystic kidney disease 1 (PKD1) gene encodes a novel protein with multiple cell recognition domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Mechanisms of nephronophthisis and related ciliopathies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Strong homophilic interactions of the Ig-like domains of polycystin-1, the protein product of an autosomal dominant polycystic kidney disease gene, PKD1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Role of TSC-mTOR pathway in diabetic nephropathy

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

mTORC1 activation in podocytes is a critical step in the development of diabetic nephropathy in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Mammalian TOR complex 2 controls the actin cytoskeleton and is rapamycin insensitive

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

TOR regulation of AGC kinases in yeast and mammals

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Effective and selective targeting of leukemia cells using a TORC1/2 kinase inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

LKB1 and AMPK family signaling: the intimate link between cell polarity and energy metabolism

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

regulation of peroxisome proliferator-activated receptor-gamma activity by mammalian target of rapamycin and amino acids in adipogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Mutual regulation of hypoxia-inducible factor and mammalian target of rapamycin as a function of oxygen availability

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Polycystin-2 is an intracellular calcium release channel

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Low-dose mTOR inhibition by rapamycin attenuates progression in anti-thy1-induced chronic glomerulosclerosis of the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

HIV-associated nephropathy: role of mammalian target of rapamycin pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

mToR inhibitors-induced proteinuria: mechanisms, significance, and management

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Proteinuria following a switch from calcineurin inhibitors to sirolimus

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Rapamycin impairs recovery from acute renal failure: role of cell-cycle arrest and apoptosis of tubular cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Rapamycin at subimmunosuppressive levels inhibits mesangial cell proliferation and extracellular matrix production.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Ischemia-reperfusion induces glomerular and tubular activation of proinflammatory and antiapoptotic pathways: differential modulation by rapamycin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Phosphorylation and functional inactivation of TSC2 by Erk implications for tuberous sclerosis and cancer pathogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Ribosomal biogenesis induction by high glucose requires activation of upstream binding factor in kidney glomerular epithelial cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Sirolimus Prolongs Recovery from Delayed Graft Function After Cadaveric Renal Transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

PKD2, a gene for polycystic kidney disease that encodes an integral membrane protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Prevalence of obesity, diabetes, and obesity-related health risk factors, 2001

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

The mTOR pathway is highly activated in diabetic nephropathy and rapamycin has a strong therapeutic potential.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

The forkhead transcription factor Foxo1 regulates adipocyte differentiation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Differential requirement of mTOR in postmitotic tissues and tumorigenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Polycystins 1 and 2 mediate mechanosensation in the primary cilium of kidney cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Transmembrane Domain Analysis of Polycystin-1, the Product of the Polycystic Kidney Disease-1 (PKD1) Gene: Evidence for 11 Membrane-Spanning Domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

PKHD1, the polycystic kidney and hepatic disease 1 gene, encodes a novel large protein containing multiple immunoglobulin-like plexin-transcription-factor domains and parallel beta-helix 1 repeats

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

DNA-dependent protein kinase-mediated phosphorylation of protein kinase B requires a specific recognition sequence in the C-terminal hydrophobic motif

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Sphinganine-1-phosphate protects kidney and liver after hepatic ischemia and reperfusion in mice through S1P1 receptor activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Nutrient sensor links obesity with diabetes risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Of mice and men: therapeutic mTOR inhibition in polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Hypoinsulinaemia, glucose intolerance and diminished beta-cell size in S6K1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Sirolimus therapy to halt the progression of ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

A critical developmental switch defines the kinetics of kidney cyst formation after loss of Pkd1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

PKD1 interacts with PKD2 through a probable coiled-coil domain

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

The molecular basis of focal cyst formation in human autosomal dominant polycystic kidney disease type I.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

The nanomechanics of polycystin-1 extracellular region.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Sirolimus reduces polycystic liver volume in ADPKD patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Failure to ubiquitinate c-Met leads to hyperactivation of mTOR signaling in a mouse model of autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Monitoring kidney and renal cyst volumes applying MR approaches on a rapamycin treated mouse model of ADPKD.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Inhibition of mTOR with sirolimus does not attenuate progression of liver and kidney disease in PCK rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Mammalian target of rapamycin inhibition prevents glomerular hypertrophy in a model of renal mass reduction.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Inhibition of mTOR signaling with rapamycin attenuates renal hypertrophy in the early diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Therapeutic targeting of mTOR in tuberous sclerosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Renal cystic disease in tuberous sclerosis: role of the polycystic kidney disease 1 gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Comparative analysis of the polycystic kidney disease 1 (PKD1) gene reveals an integral membrane glycoprotein with multiple evolutionary conserved domains

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Protective effect of 17beta-estradiol on ischemic acute renal failure through the PI3K/Akt/eNOS pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Regulation of elongation phase of mRNA translation in diabetic nephropathy: amelioration by rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Conversion from calcineurin inhibitors to sirolimus in chronic allograft dysfunction: changes in glomerular haemodynamics and proteinuria

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

The mammalian target of rapamycin (mTOR) pathway regulates mitochondrial oxygen consumption and oxidative capacity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Sirolimus and kidney growth in autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Inappropriate activation of the TSC/Rheb/mTOR/S6K cassette induces IRS1/2 depletion, insulin resistance, and cell survival deficiencies

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Pathophysiology of ischemic acute kidney injury

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

The mTOR pathway is regulated by polycystin-1, and its inhibition reverses renal cystogenesis in polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Rapamycin ameliorates PKD resulting from conditional inactivation of Pkd1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Delayed graft function and cast nephropathy associated with tacrolimus plus rapamycin use.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Rictor/TORC2 regulates fat metabolism, feeding, growth, and life span in Caenorhabditis elegans

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

A mouse model for polycystic kidney disease through a somatic in-frame deletion in the 5' end of Pkd1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Diagnosis and management of childhood polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Rapamycin markedly slows disease progression in a rat model of polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

An ATP-competitive mammalian target of rapamycin inhibitor reveals rapamycin-resistant functions of mTORC1

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Autosomal dominant polycystic kidney disease: the last 3 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Nutrients suppress phosphatidylinositol 3-kinase/Akt signaling via raptor-dependent mTOR-mediated insulin receptor substrate 1 phosphorylation

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Nutrient overload, insulin resistance, and ribosomal protein S6 kinase 1, S6K1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Absence of S6K1 protects against age- and diet-induced obesity while enhancing insulin sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Mitotic activation of Akt signalling pathway in Han:SPRD rats with polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Inhibition of mTOR with sirolimus slows disease progression in Han:SPRD rats with autosomal dominant polycystic kidney disease (ADPKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Everolimus in patients with autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

The gene mutated in autosomal recessive polycystic kidney disease encodes a large, receptor-like protein

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Cellular and subcellular localization of the ARPKD protein; fibrocystin is expressed on primary cilia.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Somatic mutation in individual liver cysts supports a two-hit model of cystogenesis in autosomal dominant polycystic kidney disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Long-term treatment of sirolimus but not cyclosporine ameliorates diabetic nephropathy in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Apoptosis and loss of renal tissue in polycystic kidney diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Polycystin-1 activates and stabilizes the polycystin-2 channel.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

The polycystic kidney disease proteins, polycystin-1, polycystin-2, polaris, and cystin, are co-localized in renal cilia

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Biochemical, cellular, and in vivo activity of novel ATP-competitive and selective inhibitors of the mammalian target of rapamycin

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Structural and molecular basis of the assembly of the TRPP2/PKD1 complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Long-term rapamycin therapy in the Han:SPRD rat model of polycystic kidney disease (PKD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Sirolimus attenuates disease progression in an orthologous mouse model of human autosomal dominant polycystic kidney disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

PDGFRs are critical for PI3K/Akt activation and negatively regulated by mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Insulin stimulates adipogenesis through the Akt-TSC2-mTORC1 pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Loss of Tsc1, but not Pten, in renal tubular cells causes polycystic kidney disease by activating mTORC1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

Uncoupling insulin signalling by serine/threonine phosphorylation: a molecular basis for insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

mTOR: from growth signal integration to cancer, diabetes and ageing

21 January 2018

1 reference

https://api.crossref.org/works/10.1152%2FAJPRENAL.00015.2012

10.1152/AJPRENAL.00015.2012

21 January 2018

Identifiers

DOI

1 reference

26 August 2017

1 reference

PubMed ID

22496407